Alessandra Piccirilli, Sabrina Cherubini, Giuseppe Celenza, Gian Maria Rossolini, Fabrizia Brisdelli, Bernardetta Segatore, Luigi Principe, Francesco Luzzaro, Lilia Andriani, Gianfranco Amicosante, Mariagrazia Perilli
Journal: Antimicrobial agents and chemotherapy 2022;66(6):e0240221
PMID: 35647648
KPC-53 enzyme is a natural KPC variant which showed a duplication of L167E168 residues in the Ω-loop structure. The gene was cloned both into pBC-SK and pET-24a vectors, and the recombinant plasmids were transferred by transformation in Escherichia coli competent cells to evaluate the antimicrobial susceptibility and to produce the enzyme. Compared to KPC-3, the KPC-53 was less stable and showed a dramatic reduction of and / versus several β-lactams, in particular carbapenems. Indeed, a 2,000-fold reduction was observed in the values of KPC-53 for imipenem and meropenem. Concerning inhibitors, KPC-53 was susceptible to tazobactam and clavulanic acid but maintained resistance to avibactam. The molecular modeling indicates that the L167E168 duplication in KPC-53 modifies the interactions between residues involved in the catalytic pocket, changing the flexibility of the Ω-loop, which is directly coupled with the catalytic properties of the KPC enzymes.
Full Text Sources:
Miscellaneous:
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.